Werfen at ICTHIC 2024

Werfen through its team in EEMEA and Italy, continued its commitment to advancing the fight against cancer-related blood clots by being a bronze sponsor at the recently concluded 12th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC 2024).

Held from May 17th to 19th, the conference served as a global platform for researchers and healthcare professionals to delve into the latest advancements in understanding, preventing, and treating blood clots in cancer patients.

Thrombosis poses a significant health risk for cancer patients, and ICTHIC 2024 provided a critical forum for sharing knowledge and developing strategies to improve patient outcomes. Werfen's sponsorship underscores their dedication to progress in the field of hematology, particularly in the fight against cancer. Their diagnostic tools play a vital role in managing blood clotting disorders, and their participation in the conference signifies their commitment to enhancing patient care.

This involvement played a crucial role in ensuring the dissemination of the latest research on thrombosis and hemostasis in cancer to a wider audience. Ultimately, Werfen's contribution to ICTHIC 2024 paves the way for better patient care and improved outcomes for cancer patients globally.

As a company focused on Powering Patient Care for Thrombosis and Hemostasis issues we are keen on highlighting the impact on outcomes of proper diagnosis and assessment of thrombotic risks. 

For more information on educational material related to the specific topic of Cancer Associated Thrombosis on our EEMEA Learning Center.

Additional Resources:

We look forward to seeing everyone in the next edition of this important conference.

Elias El Bouchi, Marketing Manager Hemostasis

Last modified on Tuesday, 24 February 2026 11:37

 

All rights reserved. © werfen.com

Get in touch

with the EEMEA team:

eemea@werfen.com

 

werfenplain

Issues

Go to top